Correction

NEUROSCIENCE, PSYCHOLOGICAL AND COGNITIVE SCIENCES


The authors note that the author name Gustavo Angarita-Africano should instead appear as Gustavo A. Angarita. The corrected author line appears below. The online version has been corrected.

Margaret T. Davis, Ansel Hillmer, Sophie E. Holmes, Robert H. Pietrzak, Nicole DellaGioia, Nabeel Nabulsi, David Matuskey, Gustavo A. Angarita, Richard E. Carson, John H. Krystal, and Irina Esterlis

Published under the PNAS license.
Published online June 17, 2019.

www.pnas.org/cgi/doi/10.1073/pnas.1909442116
Recent evidence implicates dysregulation of metabotropic glutamatropic receptor 5 (mGluR5) in pathophysiology of PTSD and suicidality. Using positron emission tomography and [18F]FPEB, we quantified mGluR5 availability in vivo in individuals with PTSD (n = 29) and MDD (n = 29) as a function of suicidal ideation (SI) to compare with that of healthy comparison controls (HC; n = 29). Volume of distribution was computed using a venous input function in the five key frontal and limbic brain regions. We observed significantly higher mGluR5 availability in PTSD compared with HC individuals in all regions of interest (P = 0.001–0.01) and compared with MDD individuals in three regions (P = 0.007). mGluR5 availability was not significantly different between MDD and HC individuals (P = 0.17). Importantly, we observed up-regulation in mGluR5 availability in the PTSD-SI group (P = 0.001–0.007) compared with PTSD individuals without SI. Findings point to the potential role for mGluR5 as a target for intervention and, potentially, suicide risk management in PTSD.

Results

Posttraumatic stress disorder (PTSD) is an important risk factor for suicidal ideation, attempts, and death by suicide (1, 2). Despite awareness of this risk, there is limited understanding of the biology underlying suicidality in PTSD. As a result, there are limited pharmacologic options to treat individuals with PTSD at high risk for suicide. Thus, there is an urgent need to study the neurobiology of suicidality in PTSD.

The metabotropic glutamate receptor type 5 (mGluR5) has emerged as a target of interest for PTSD and suicide research. mGluR5 is implicated in mood and anxiety symptoms in both human (3, 4) and animal studies (5, 6). We recently reported significantly higher mGluR5 availability in individuals with PTSD relative to matched controls across many brain regions (4). Also, a postmortem work found up-regulation of mGluR5 gene expression in the locus coeruleus associated with suicide in tissue from depressed individuals (7). mGluR5 activation moderates the function of N-methyl-D-aspartate glutamate receptors (NMDA-R) (8–10), an ionotrophic glutamate receptor critical to synaptic plasticity (11, 12) and emotional learning (13, 14). NMDA-R functioning has also been implicated in the pathophysiology of suicidal behavior (15–17). The NMDA-R antagonist, ketamine, has demonstrated efficacy in reducing suicidal ideation. Also, a polymorphism in the GRIN2B gene was associated with both impulsivity (18) and suicide attempt (19). Thus, dysregulation in mGluR5 may affect the development of suicidal behavior both directly and through downstream effects. However, the relationship between mGluR5 and suicidal behavior including suicidal ideation, in individuals with PTSD or other psychiatric diagnosis, has not been explored in vivo.

The present study used positron emission tomography (PET) to examine the relationship between mGluR5 availability and suicidal ideation in vivo in individuals with PTSD compared to those with major depressive disorder (MDD). Using [18F]FPEB—a radioligand with high selectivity and specificity (20)—for the negative allosteric modulator site on mGluR5—we sought to quantify mGluR5 availability in three groups of individuals: those with (i) Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) PTSD with or without MDD, (ii) DSM-5 MDD without PTSD, and (iii) healthy comparison controls (HC). Based on our previous work (4, 3), we hypothesized that mGluR5 availability would be higher in individuals with PTSD relative to MDD and HC. Furthermore, we hypothesized that greater dysregulation in mGluR5 availability would be observed in individuals with suicidal ideation (SI) in the PTSD group. We also sought to examine whether dysregulation in mGluR5 availability would be associated with symptoms of PTSD and suicidality, such as anxiety and avoidance.

Significance

Posttraumatic stress disorder (PTSD) is an important risk factor for suicidal ideation, attempts, and death by suicide. Understanding the biology underlying suicidality in PTSD is limited. In this study, we used positron emission tomography to evaluate the metabotropic glutamate receptor type 5 (mGluR5) as a potential treatment target and biomarker of suicidal ideation in individuals with PTSD and major depressive disorder (MDD). We found higher availability of mGluR5 in individuals with PTSD relative to healthy control and MDD groups. Furthermore, higher mGluR5 availability was associated with scan-day suicidal ideation among individuals with PTSD, but not MDD. Findings identify mGluR5 as a biomarker for intervention and potentially suicide risk management in PTSD.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Published under the PNAS license.

1To whom correspondence should be addressed. Email: irina.esterlis@yale.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1818871116/-/DCSupplemental.

Published online May 13, 2019.
PFC (vmPFC), an average of 19% higher (see Table 1 for mean regional VT values, % differences, and Cohen’s d values). Similarly, mGluR5 availability was higher in the PTSD group compared with MDD in the orbitofrontal cortex (OFC) (15%, P = 0.007), dlPFC (17%, P = 0.007), and hippocampus (15%, P = 0.007; SI Appendix, Table S1). There were no differences in mGluR5 availability between the MDD and HC groups (1–8% difference, P’s = 0.25–0.60), as previously shown by our group and others (3, 21).

To evaluate the relationship between mGluR5 availability and SI, ANOVAs with brain regions as dependent variables and SI as the independent variable were conducted within each clinical group. The main effect of SI was significant in the PTSD group (F7,16 = 4.03, P = 0.01), but not the MDD group (F8,16 = 0.27, P = 0.96; Table 1 and SI Appendix, Fig. S1). Post hoc tests in the PTSD group revealed significantly higher mGluR5 availability in individuals reporting scan-day SI in each of the five regions of interest (P values ranging from 0.001 to 0.007, average 24% difference; Fig. 1, Table 1, and SI Appendix, Fig. S2). In keeping with results from our prior work, we found a significant positive correlation between mGluR5 availability and scores on the avoidance subscale of the PTSD checklist for DSM-5 (PCL-5) in the vmPFC (r = 0.57, P = 0.007). Finally, peripheral cortisol samples were collected from plasma in the PTSD group at the beginning of the scan day and again immediately before scan. Cortisol levels at scan time were inversely correlated with mGluR5 availability in dlPFC (r = −0.69, P = 0.02) and OFC (r = −0.72, P = 0.02).

Secondary Analyses. We conducted further analyses to investigate relationships between mGluR5 availability and suicide-related endophenotypic variables. Interestingly, we observed a divergent pattern of associations between mGluR5 availability and both total and subscales on the Profile of Mood States (POMS) in PTSD compared with MDD groups. POMS total score (POMS-total) was positively correlated with mGluR5 availability in the PTSD group (vmPFC, r = 0.60, P < 0.001; Fig. 2) and inversely correlated with mGluR5 availability in the MDD group (vmPFC, r = −0.64, P = 0.003; dlPFC, r = −0.67, P = 0.002; hippocampus, r = −0.55, P = 0.01). Similarly, PTSD group mGluR5 availability was positively correlated with subscores on the POMS tension (POMS-T) (vmPFC, r = 0.53, P = 0.007) and anxiety (POMS-A) (vmPFC, r = 0.47, P = 0.008) subscales in various regions, while inverse correlations were observed in the MDD group for both subscales (POMS-T: dlPFC, r = −0.52, P = 0.01; vmPFC, r = −0.57, P = 0.01; POMS-A: dlPFC, r = −0.55, P = 0.01; OFC, r = −0.38, P = 0.01). Upon further examination, we detected that the association between mGluR5 availability and POMS-total in the PTSD group was driven by the PTSD-SI group (vmPFC, r = −0.72, P = 0.005); no significant association between POMS-total and mGluR5 availability was observed in individuals without SI in the

### Table 1. Regional [18F]FPEB VT and significance values across reported suicidal ideation in both PTSD and MDD groups

<table>
<thead>
<tr>
<th>Region</th>
<th>MDD-No SI, n = 14</th>
<th>MDD-SI, n = 15</th>
<th>PTSD-No SI, n = 15</th>
<th>PTSD-SI, n = 14</th>
<th>Cohen’s d (PTSD)</th>
<th>P value (PTSD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>dlPFC</td>
<td>33.63 (6.04)</td>
<td>33.84 (9.39)</td>
<td>32.71 (6.80)</td>
<td>43.18 (7.01)</td>
<td>1.51</td>
<td>0.001</td>
</tr>
<tr>
<td>vmPFC</td>
<td>32.11 (5.64)</td>
<td>32.34 (8.54)</td>
<td>31.39 (6.59)</td>
<td>40.81 (7.65)</td>
<td>1.34</td>
<td>0.001</td>
</tr>
<tr>
<td>OFC</td>
<td>30.64 (5.32)</td>
<td>30.60 (8.78)</td>
<td>30.39 (6.21)</td>
<td>38.46 (3.94)</td>
<td>1.55</td>
<td>0.003</td>
</tr>
<tr>
<td>Amygdala</td>
<td>26.83 (4.93)</td>
<td>27.23 (7.22)</td>
<td>26.75 (5.38)</td>
<td>32.93 (4.84)</td>
<td>1.21</td>
<td>0.007</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>24.62 (5.61)</td>
<td>25.01 (6.01)</td>
<td>24.49 (5.25)</td>
<td>30.26 (5.15)</td>
<td>1.11</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Mean (SD) reported. dlPFC, dorsolateral prefrontal cortex; OFC, orbitofrontal cortex; vmPFC, ventromedial prefrontal cortex.

Fig. 1. mGluR5 availability among PTSD individuals (with and without suicidal ideation), MDD individuals (with and without SI), and matched HCs in representative regions: (A) hippocampus; (B) amygdala; (C) dorsolateral prefrontal cortex; (D) ventromedial prefrontal cortex. Percentage differences reflect PTSD: SI vs. HC and MDD-SI vs. PTSD-SI. Error bars represent SD.
PTSD group. To further examine the relationship between SI, mGluR5 availability, and POMS-total (mood variability), we repeated the primary analysis examining mGluR5 availability in PTSD-SI and PTSD without SI with POMS-total score included in the model. Results were similar to the original analysis in the PTSD group; the main effect of SI was significant ($F_{5,19} = 3.58, P = 0.02$), while the main effect of POMS-total ($F_{5,19} = 2.37, P = 0.09$) and the interaction of POMS-total $\times$ SI ($F_{5,19} = 1.38, P = 0.27$) were not.

Discussion

In this investigation, we observed significantly higher mGluR5 availability in PTSD relative to both HC and MDD individuals in frontolimbic brain regions. These findings both confirm and extend results of our previous in vivo study, which showed mGluR5 up-regulation in PTSD relative to HC. Significantly, here we show that higher mGluR5 availability was also associated with scan-day suicidal ideation in the PTSD group only: PTSD-SI individuals exhibited significantly up-regulated frontolimbic mGluR5 availability compared with PTSD individuals without SI. No difference in mGluR5 availability was observed as a function of SI in the MDD group. Furthermore, dysregulation in mGluR5 in PTSD was associated with suicide-related endophenotypes including mood disturbance and anxiety. Thus, mGluR5 may represent a promising treatment target for the reduction of suicidal ideation in PTSD specifically.

At present, the mechanisms by which mGluR5 may be up-regulated in PTSD and in suicidal ideation in those with PTSD are not well understood. However, we hypothesize a combination of depression in hypothalamic-pituitary-adrenal (HPA) axis function (22–24) and up-regulation in scaffolding proteins that traffic and lock mGluR5 at the membrane (25, 26) might contribute to dysregulation in mGluR5 availability in PTSD suicidality. There is support for prominent differences between PTSD and MDD in HPA axis regulation. Specifically, studies suggest reduced glucocorticoid signaling in PTSD. For example, both epigenetic and postmortem studies suggest that down-regulation of FKBP5, a gene that controls the sensitivity of glucocorticoid receptors to cortisol, is associated with PTSD (27). Furthermore, FKBP5 has been shown to interact with childhood trauma exposure to increase risk for suicide attempt (28). By contrast, there is significant evidence of HPA axis hyperactivity in MDD, including heightened basal cortisol relative to comparison controls (29). These differences in cortisol level may help explain observed differences in mGluR5 availability across diagnostic groups; both the HPA axis and adrenal glucocorticoid system function may regulate glutamatergic neurotransmission, and therefore mGluR5 availability. Preclinical literature suggests that administration or stimulated release (30) of corticosterone reduces expression of mGluR5. Consistent with preclinical work, we observed an inverse correlation between mGluR5 availability and cortisol in PTSD individuals. Our preliminary data suggest that the reduced levels of cortisol in PTSD may contribute to mGluR5 up-regulation via trafficking and stabilization of mGluR5 at the cell surface. Specifically, we found up-regulation of the SHANK-1 (a glutamatergic scaffolding protein) gene in PTSD individuals postmortem (4). Notably, HPA axis hypofunction, as observed in PTSD, has also been associated with suicidal behavior; studies suggest reduced glucocorticoid signaling in PTSD, and down-regulation of FKBP5 has been associated with risk for suicide attempt (28, 31, 32) and death by suicide (33, 34). Other insight into the relationship between suicidal behavior and mGluR5 might come from two candidate gene studies that have suggested that genetic alterations in the scaffolding protein Homer1 may be associated with suicide attempts (35, 36). Similarly, PSD-95, another glutamatergic scaffolding protein, has been associated with death by suicide (15). Together, while preliminary, these findings suggest that the location of mGluR5 (at the synapse versus internalized) may play a significant role in suicidality in PTSD. Taken together, these findings support the possibility that mGluR5 up-regulation in PTSD and suicidality occurs as a result of a combination of mGluR5 location at the cell and dampened glucocorticoid signaling.

![Fig. 2](https://www.pnas.org/cgi/doi/10.1073/pnas.1818871116)

Fig. 2. (A) Positive association between mGluR5 availability in the vmPFC and score on the tension subscale of the POMS (POMS-T) among individuals with PTSD. (B) Negative association between mGluR5 availability in the vmPFC and POMS-T score among individuals with MDD. (C) Positive association between mGluR5 availability in the vmPFC POMS-total score among individuals with PTSD. (D) Negative association between mGluR5 availability in the vmPFC and POMS-total score among individuals with MDD.
With respect to suicidal ideation, the contrast in our findings across MDD and PTSD groups raises a crucial question: Is the neurobiology of suicide consistent across psychiatric diagnoses? A recent review of gene wide association studies that focused on suicide in both MDD and bipolar depression revealed inconsistent genetic findings and infrequent replication of results across studies (37). One possible explanation for such discrepancies concerns the failure to account for common comorbid diagnoses such as PTSD and other anxiety disorders. If the neurobiology of suicide varies as a function of psychiatric diagnosis, the failure to account for comorbidity could bias results. Our findings arguably provide some support for the presence of distinct neurobiological pathways to suicidal behavior: mGluR5 was associated with suicidal ideation in PTSD, but not MDD. Importantly, it is also possible that distinct pathways to suicidal behavior exist but are not directly related to diagnostic status. For example, Fudalej et al. (33) found that the association between a specific gene and death by suicide was stronger in individuals who were intoxicated at time of death. They argued that the differences in strength of association pointed to different neurobiological signatures for impulsive (more commonly associated with intoxication) versus planned suicide. Further work is needed before a definitive conclusion concerning sources of variability in the neurobiological mechanisms underlying suicide can be reached.

Careful characterization of the essential elements of constructs like SI and attempt (e.g., ideation reflecting hopelessness, ideation reflecting feeling overwhelmed, lethality of attempt method) should also be a priority of future work. In our sample, we observed a relationship between SI and POMS-total (mood variability) in the PTSD group. However, no significant interaction between POMS-total and SI was observed in ANOVA analyses. Thus, while SI in PTSD was related to mood variability in our sample, mood variability did not account for or significantly impact the relationship between SI and mGluR5 availability. We also examined bivariate relationships between SI and other relevant clinical variables in an effort to understand the nature of the construct (e.g., whether ideation in PTSD individuals in this sample reflected hopelessness, occurred in those with more severe symptom presentation, etc.). SI was not associated with PTSD or depressive symptom severity [Clinician Administered PTSD Scale for DSM-5 (CAPS) or Montgomery–Asberg Depression Scale (MADRS) total scores], hopelessness, or working memory or executive dysfunction. Future work should continue to explore the nature of SI in PTSD and in relation to mGluR5 availability.

Our exploratory findings also hold potentially significant implications for both research and treatment. We observed differential associations between mGluR5 availability and symptoms of depression and anxiety in PTSD and MDD groups. The observed pattern of findings suggests a potentially distinct role for mGluR5 in the pathology of PTSD relative to MDD. Higher frontolimbic mGluR5 was associated with more severe symptom experience across a number of domains in the PTSD group. The association between mGluR5 availability and symptoms of avoidance, also observed in our previous study, is particularly notable: relative to other symptom clusters, symptoms of avoidance have a stronger relationship with functional impairment (38, 39). Observed associations in the PTSD group are consistent with preclinical literature, which implicates mGluR5 in fear conditioning (5, 40, 41) and suggests that antagonism of mGluR5 can produce anxiolytic effects (42–44). Together, these findings support the potential importance of exploring down-regulation of mGluR5 as a treatment for symptom reduction in PTSD. By contrast, in MDD, lower frontolimbic mGluR5 availability was associated with more severe symptom presentation in a number of domains. In vivo findings of mGluR5’s role in MDD have been mixed (3, 45, 46), likely due to the difference in sample demographics. The role and significance of mGluR5 in the pathophysiology of MDD thus warrants additional exploration to clarify discrepant findings.

A number of study limitations should be noted. First, the participants were matched for age, sex, and smoking status, but not for history of trauma exposure. Future research should consider the potential impact of trauma exposure on mGluR5 availability in individuals who do not meet diagnostic criteria for PTSD. Second, diurnal variation has been shown to affect mGluR5 availability. We attempted to scan participants at roughly the same time of day (13:36 ± 2.3 h) to control for this potential confound. Third, analyses confirmed no significant differences on the noted variables between PTSD individuals and either HC or MDD individuals. BMI, Body Mass Index; CAPS, Clinician Administered PTSD Scale; HAM-D, Hamilton depression rating scale; PCL, PTSD Checklist; MADRS, Montgomery–Asberg Depression Rating Scale; M:F, male:female.

### Table 2. PET study participant characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>PTSD, n = 29</th>
<th>PTSD-SI, n = 14</th>
<th>PTSD-No SI</th>
<th>MDD, n = 29</th>
<th>MDD-SI, n = 15</th>
<th>MDD-No SI</th>
<th>Healthy Controls, n = 29</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M:F)</td>
<td>16:13</td>
<td>6:8</td>
<td>10:5</td>
<td>14:15</td>
<td>6:9</td>
<td>8:6</td>
<td>14:15</td>
<td>0.47</td>
</tr>
<tr>
<td>Age, y</td>
<td>35.55 (9.72)</td>
<td>32.38 (6.37)</td>
<td>38.35 (10.60)</td>
<td>36.69 (13.98)</td>
<td>40.31 (14.24)</td>
<td>35.63 (13.72)</td>
<td>37.39 (12.01)</td>
<td>0.84</td>
</tr>
<tr>
<td>No. of smokers</td>
<td>7</td>
<td>4</td>
<td>3</td>
<td>7</td>
<td>4</td>
<td>3</td>
<td>6</td>
<td>0.42</td>
</tr>
<tr>
<td>Medicated</td>
<td>11</td>
<td>4</td>
<td>7</td>
<td>6</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>0.82</td>
</tr>
<tr>
<td>BMI (scan day)</td>
<td>30.55 (5.57)</td>
<td>30.02 (7.03)</td>
<td>31.00 (4.59)</td>
<td>27.83 (5.40)</td>
<td>29.25 (4.56)</td>
<td>27.20 (5.65)</td>
<td>27.22 (3.28)</td>
<td>0.16</td>
</tr>
<tr>
<td>CAPS</td>
<td>68.23 (23.45)</td>
<td>70.05 (13.50)</td>
<td>62.37 (20.05)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PCL-S</td>
<td>54.1 (12.7)</td>
<td>57.30 (8.50)</td>
<td>39.10 (13.50)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MADRS</td>
<td>19.41 (7.46)</td>
<td>20.08 (8.20)</td>
<td>19.07 (7.44)</td>
<td>20.63 (8.65)</td>
<td>23.56 (6.67)</td>
<td>19.90 (7.34)</td>
<td>-</td>
<td>0.61</td>
</tr>
<tr>
<td>HAM-D</td>
<td>15.53 (6.63)</td>
<td>16.22 (6.12)</td>
<td>14.90 (7.34)</td>
<td>18.83 (4.62)</td>
<td>17.75 (4.99)</td>
<td>21.00 (4.24)</td>
<td>21.00 (4.24)</td>
<td>-0.27</td>
</tr>
</tbody>
</table>

*Mean (SD) reported. *P* values obtained from independent-sample *t* tests comparing PTSD, MDD, and HC (where applicable). Subsequent analyses confirmed no significant differences on the noted variables between PTSD individuals and either HC or MDD individuals.
dysregulation and anxiety. Direct and indirect treatments that might regulate mGluR5 have been investigated for other disorders (49–51), and thus pharmacutes that might regulate mGluR5 are readily available for human clinical trials. The next step in this work might be to examine whether down-regulating mGluR5 via one of these mechanisms might aide with decreases in PTSD symptoms. Given the paucity of Food and Drug Administration-approved treatments for PTSD and the high risk of suicidality, continued investigation of the role of the glutamatergic system, and mGluR5 specifically, as targets for treatment and suicide risk management in PTSD should be prioritized.

**Methods**

**Participants.** Twenty-nine individuals with PTSD (mean ± SD age = 35.55 ± 9.72 y; 16 females), 29 individuals with MDD (mean ± SD age = 36.69 ± 13.98 y; 14 females), and 29 healthy comparison control participants (mean ± SD age = 37.39 ± 12.01 y; 14 females) completed the study. Groups were matched by age, race, sex, and smoking status (Table 2). Sixteen of the 29 individuals with PTSD met the criteria for MDD. Of note, some participants (MDD, n = 18 (22); PTSD, n = 16 (21); HC, n = 18 (21, 22)) were also included in samples reported on previously. Eight individuals within the MDD group met criteria for comorbid DSM-5 anxiety disorders. Eleven PTSD participants and 6 MDD participants were medicated (using selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors) at the time of the study. Participants ranged in age from 18 to 55 (see Table 2 for additional demographic information). All participants completed physical, psychiatric, and neurological examination at an initial screening visit to establish diagnosis and rule out any major medical or neurological illnesses. Screening included electrocardiography, complete blood counts, serum chemistries, thyroid function test, liver function test, urinalysis and urine toxicology screening, and plasma pregnancy tests (for women). Diagnosis was confirmed using the Structured Clinical Interview for DSM-5 (52).

Symptoms were further assessed using the MADRS-S (53), the PCL-5 (54), the CAPS-5 (53), and the POMS (56), a measure of mood disturbance. The presence of a significant amount or severity of one or more of the criteria for PTSD, MDD, or anxiety was confirmed using the Structured Clinical Interview for DSM-5 (52).

**PET Image Analysis.** All PET images were first coregistered to participant’s T1-weighted MRI images using a six-parameter mutual information algorithm (FLIRT, FSL 3.2, Analysis Group, FMRIIB). Images were then coregistered to the MR template via nonlinear transformation using the Bioimagesuite software (version 2.5; www.bioimagesuite.com). Regions of interest were identified and normalized to the anatomical Atlas for controlling for differences in brain size and shape. Below, primary regions of interest included three subdivisions of the prefrontal cortex: vmPFC, OFC, and dIPFC, as well as the hippocampus and amygdala. Gray matter segmentation was conducted using the computational anatomy toolbox for SPM2 (CAT). No appropriate reference region completely devoid of mGluR5 is available in the human brain (60). As such, our outcome measure was calculated as volume of distribution (Vr; ratio of metabolite-corrected radiogand concentration in region of interest to radiogand concentration in plasma, calculated at equilibrium). Vr was estimated using the equilibrium analysis method with venous input function (3, 4, 20).

No differences were observed in free fraction in plasma. Therefore, as previously, [11C]FPEB represents mGluR5 availability.

**Statistical Analysis.** Statistical analyses were completed using SPSS Statistics v22 (IBM). For the PET portion of the study, independent-sample t tests and one-way ANOVAs were used to assess differences between demographic and clinical characteristics across groups. Primary analyses focused on five brain regions, selected on the basis of the strength of empirical evidence supporting their role in the pathophysiology of both PTSD and suicidal behavior, including ideation (61–63). This included three frontal/cortical regions (dIPFC, vmPFC, and OFC) and two subcortical regions (amygdala and hippocampus). Group differences in mGluR5 availability were assessed using an ANOVA with group as the independent variable and Tukey’s HSD post hoc comparison tests. Within-group differences in SI were similarly evaluated using multivariate ANOVAs performed separately in MDD and PTSD groups with brain regions as dependent variables and SI as the independent variable. In both cases, Tukey’s HSD tests were again performed to evaluate region-specific differences. Finally, to explore potentially meaningful associations between mGluR5 availability and clinical and demographic variables, Pearson correlations were used after we confirmed (using Kolmogorov–Smirnov tests) that primary variables of interest were normally distributed. A Bonferroni correction was used for all post hoc tests to control for potential family-wise error. A priori power analyses confirmed a minimum of 80% power to conduct all planned analyses.

**ACKNOWLEDGMENTS.** We thank the staffs at the Yale PET Center, the National Center for PTSD (West Haven Campus), and the Yale Center for Clinical Investigation (YCCI) for their help with the individuals who took part in the PET study. Funding support was provided by the Veterans Affairs National Center for PTSD (R.H.P., R.S.D., J.H.K., and I.E.), National Institute of Mental Health (NIMH) Grants K01MH092681 and R01MH104459 (to I.E.) and K08 MH117351-01 (to M.T.D.), National Institute on Drug Abuse Grant T32 DA022975-9 (to M.T.D.), a Dana Foundation Grant (to I.E.), and the YCCI.


---

**11494 | www.pnas.org/cgi/doi/10.1073/pnas.1818871116**

**Davis et al.**

---


---


---


---


325. Uszlany JM, et al. (2009) Dose-dependent effect of CDPPB, the mGlu5 receptor agonist, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57:531–538.


